N-acetylneuraminate synthaseGenealiases: HEL-S-100 · SAS · SEMDCG · SEMDG
Q-omics provides the consensus-scored NANS profile across patient tissues and cancer cell-line models. NANS expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NANS is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, NANS protein abundance shows 28,119 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KIRC, and PDAC as cancer lineages where NANS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NANS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NANS survival associations across molecular data types. NANS RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NANS RNA expression–survival associations across cancer types. High NANS expression shows unfavorable associations in UVM, ACC, LUAD, LIHC and KICH, but favorable associations in UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NANS RNA expression.
This table summarizes NANS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NANS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NANS shows lower tumor expression in COAD and higher tumor expression in KIRC, KIRP, LIHC, BRCA and LUAD. The KIRC box plot shows higher NANS RNA expression in tumor versus normal tissue (log2 FC = +0.757, t-test p < 0.001).
This table shows molecular features associated with NANS in patient tissues and cancer cell lines. In patient samples, NANS shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, NANS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
